Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes.
Farina A, Villagrán-García M, Vogrig A, Zekeridou A, Muñiz-Castrillo S, Velasco R, Guidon AC, Joubert B, Honnorat J.
Lancet Neurol. 2024 Jan;23(1):81-94. doi: 10.1016/S1474-4422(23)00369-1.
Paraneoplastic movement disorders.
Popławska-Domaszewicz K, Florczak-Wyspiańska J, Kozubski W, Michalak S.
Rev Neurosci. 2018 Sep 25;29(7):745-755. doi: 10.1515/revneuro-2017-0081.
Mechanism, and treatment of anti-CV2/CRMP5 autoimmune pain.
Martin L, Stratton HJ, Gomez K, Le Duy D, Loya-Lopez S, Tang C, Calderon-Rivera A, Ran D, Nunna V, Bellampalli SS, François-Moutal L, Dumaire N, Salih L, Luo S, Porreca F, Ibrahim M, Rogemond V, Honnorat J, Khanna R, Moutal A.
bioRxiv [Preprint]. 2024 May 7:2024.05.04.592533. doi: 10.1101/2024.05.04.592533.
Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study.
Farina A, Villagrán-García M, Fourier A, Pinto AL, Chorfa F, Timestit N, Alberto T, Aupy J, Benaiteau M, Birzu C, Campetella L, Cotton F, Dalle S, Delaruelle CF, Dumez P, Germi R, Le Maréchal M, Maillet D, Marignier R, Pegat A, Psimaras D, Rafiq M, Picard G, Desestret V, Quadrio I, Honnorat J, Joubert B.
Lancet Reg Health Eur. 2024 Jul 25;44:101011. doi: 10.1016/j.lanepe.2024.101011. eCollection 2024 Sep.
Updates in the Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes.
Grativvol RS, Cavalcante WCP, Castro LHM, Nitrini R, Simabukuro MM.
Curr Oncol Rep. 2018 Nov 10;20(11):92. doi: 10.1007/s11912-018-0721-y.
The Clinical Spectrum of Autoimmune-Mediated Neurological Diseases in Paediatric Population.
Lubarski K, Mania A, Michalak S, Osztynowicz K, Mazur-Melewska K, Figlerowicz M.
Brain Sci. 2022 Apr 29;12(5):584. doi: 10.3390/brainsci12050584.
